Jylamvo 2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals. Information to minimise the risk of medication error
|
|
- Mavis Hill
- 5 years ago
- Views:
Transcription
1 2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals Information to minimise the risk of medication error NOTE: Special warnings and precautions for use - This oral solution contains 2 in each ml of solution - The scaling of the dosing syringe is in ml and not mg - Care must be taken that the correct dosing volume is prescribed. - Patients with rheumatological or dermatological diseases must be informed unequivocally that treatment is to be taken just once a week and not daily. - Incorrect use of can result in severe and even fatal adverse reactions. - Medical staff and patients must be clearly instructed. Date HPRA Approval: September 2017 Page 1 of 7
2 1. Purpose of this guide This Guide is provided by Therakind Ltd for doctors, nurses and other healthcare professionals who prescribe, dispense or work with patients who use (Methotrexate) and is intended to ensure that the medicine is used correctly. The main objective of this guide is to help mitigate against the potential risk of medication errors. Please be aware of the special warnings and precautions for use detailed on the cover of this guide. All healthcare professionals are further referred to the Summary of Product Characteristics (SmPC) and Patient Leaflet (PL) accompanying this Guide for full prescribing information. 2. Prescribing ( 2mg/ml) is available as an oral solution that contains 2 mg/ml of is taken once a week (on the same day each week) to treat: Rheumatoid arthritis [RA] Juvenile idiopathic arthritis [JIA] Psoriasis Only for acute lymphoblastic leukaemia (ALL) should the medicine be taken at higher doses and more frequently. The prescribing physician is responsible for determining which patients are suitable for home or selfadministration of. Each patient/carer should be assessed to determine whether they are able to measure the dose correctly. Only after such an assessment should patients/carers start to administer at home. Potential causes for medication errors with this product include: Inadvertent daily dosing (in arthritis and psoriasis indications) Overdose due to confusing mg and ml 3. Working out and measuring the correct dose Children: dosing is prescribed by body surface area (BSA) (please see appendix A). Adults: dosing is prescribed as a fixed dose. Dosing syringe: One syringe is provided with the product which must be used to withdraw the dose: a 10ml syringe with major graduations at every 1ml and minor graduations at every 0.25 ml. This allows delivery of the required dose volume range appropriately and accurately. Detailed instructions on measuring and administering the correct dose with the syringe are provided in the Package Leaflet and SmPC. Points to consider: The syringe is graduated in ml while the dose is expressed in mg Each ml of solution contains 2 mg Prescribe in mg and ml in order to avoid overdosing due to medication error; For arthritis and psoriasis patients, include the day of the week that the patient should take the dose on the prescription. Date HPRA Approval: September 2017 Page 2 of 7
3 The tables in Appendix A are provided to assist in working out dosage in mg and ml (by BSA) for children/adolescents being treated for JIA and ALL, respectively 4. What to discuss with patients for home use or self-administration Direct the patient/carer to the Package Leaflet and especially section 3 for instructions on how the patient should take the medication. It is important to carefully explain to patient/carer When and how they should take their dose How to withdraw a dose from the bottle using the syringe provided to ensure it is accurately measured To only use the syringe provided with the product That this product is cytotoxic and that both the product and syringe must be handled and disposed of carefully and safely (See additional points on handling and disposing of, section 6) The types of side effects/symptoms that might indicate the early signs of overdose toxicity such as bleeding, unusual feeling of weakness, ulcers in the mouth, feeling sick, vomiting, black or bloody stools, coughing up blood or vomiting blood and reduced urinary output (see section 4 of Package Leaflet) and advise them to contact a doctor/pharmacist immediately if they experience those side effects That they should tell their doctor immediately or contact the nearest hospital casualty department if they have any signs or symptoms of overdose (eg. bleeding etc) or if they know or suspect that they (or someone else) have taken too much and that they should write down what they took and when The patient/carer should be assessed to ensure they are able to withdraw and measure the prescribed dose correctly using the syringe provided. Only following this should patients/carers start to self-administer at home. For arthritis and psoriasis patients, it is very important to remind the patient/carer and to be sure that they have understood: The need to maintain the prescribed dosing regimen of That greater doses may be associated with an increased risk of side effects, the potential for severe side effects and even death That it is a weekly regime ( is never taken every day for arthritis or skin diseases) Which same day of the week the dose should be taken on each week 5. PHARMACISTS - Dispensing ( 2mg/ml) Recommendations for dispensing: Always double check the prescription describes an appropriate dose in mg and ml Ensure the day of the week the dose should be taken is included on the label, if appropriate Open the container and show the actual medication and syringe to the patient/carer Reiterate the dosing regime with the patient/carer and show them the ml gradations on the syringe as you explain the dosing Emphasize that they should only use the dosing syringe provided with the product to measure the dose Check to see they have understood The importance of adhering to the correct dose and frequency should be discussed with the patient/carer Date HPRA Approval: September 2017 Page 3 of 7
4 Refer the patient/carer to the list of side effects in section 4 of the Package Leaflet and advise that they should contact a doctor/pharmacist immediately if side effects are experienced Suggest that if the patient/carer does accidently make an error that they write down what they took and when and to contact a doctor immediately ( as a precaution ) Discuss safe handling and disposal of the product and syringe (See additional points on handling and disposing of Methotrexate, section 6) Points to consider: Methotrexate is never taken every day for arthritis or skin diseases, it is prescribed as a weekly dosing regime Weekly dosing should be taken on the same day of the week The syringe is marked in ml and not mg Dosing guidance by children/ adolescents BSA for JIA and ALL are provided in Appendix A 6. Additional points on handling and disposing of Methotrexate Wash hands before and after administering a dose. Disposable gloves should be worn when handling If comes into contact with skin or mucosa, it should be washed immediately and thoroughly with soap and water Keep the bottle tightly closed and wipe spillages immediately Wash the syringe immediately after use following the instructions in Section 3 of the Package Leaflet Women who are pregnant, planning to be or breast-feeding should not handle Store out of reach of children and ideally in a locked cabinet Any unused medicinal product and used bottles/syringes should be disposed of in accordance with local requirements for cytotoxic products 7. Follow-up visits and medication errors Patients should be monitored for signs and symptoms of overdose (these predominantly affect the haematopoietic and gastrointestinal systems), such as bleeding, unusual feeling of weakness, ulcers in the mouth, feeling sick, vomiting, black or bloody stools, coughing up blood or vomiting blood and reduced urinary output. 8. Therapeutic management of overdose Calcium folinate is the specific antidote for neutralising the adverse toxic effects of. In the event of overdose, a dose of calcium folinate equal to or higher than the offending dose of should be administered intravenously or intramuscularly within 1 hour, and dosing continued until serum levels of are below 10-7 mol/l. In the event of a massive overdose, hydration and alkalinisation of the urine may be required to prevent precipitation of and/or its metabolites in the renal tubules. Neither haemodialysis nor peritoneal dialysis has been shown to improve the elimination of. Effective clearance of is reported to be achieved with acute intermittent haemodialysis using a high-flux dialyser. Date HPRA Approval: September 2017 Page 4 of 7
5 9. Adverse event reporting ( 2mg/ml) even at the correct dose can cause Adverse Reactions and it is important to report any and all Adverse Events (even if the causal relationship is in doubt - if it is in doubt, then please state this in the report). Suspected adverse reactions should be reported to the HPRA using a Yellow Card obtained either from the HPRA, or electronically via the website at Adverse reactions can also be reported to the HPRA by calling (01) Adverse reactions can also be reported to Therakind (drugsafety@therakind.com) or their distributor Intrapharm Laboratories Ltd (see Medical Information enquiries contact details below for telephone, fax and contact details). 10. Where can I obtain more information? For all Medical Information enquiries or to report an Adverse Reaction, please see the contact details on the Therakind website ( or contact Therakind s Distributor, Intrapharm Laboratories on: Tel: +44 (0) Fax: +44 (0) medinfo@intrapharmlabs.com Additional copies of this Guide can be obtained using the above contact details. Date HPRA Approval: September 2017 Page 5 of 7
6 Body Surface Area (m 2 ) APPENDIX A Dosing Guidance for Children and Adolescents in the Treatment of JIA and ALL Dosing guidance for Juvenile Idiopathic Arthritis COMMONLY PRESCRIBED DOSES 10mg/m 2 15mg/m 2 20mg/m * * * * * * * * * * * * * * * * * * * * * dose rounded down Date HPRA Approval: September 2017 Page 6 of 7
7 Body Surface Area (m 2 ) Dosing guidance for Acute Lymphoblastic Leukaemia COMMONLY PRESCRIBED DOSES 20mg/m 2 30mg/m 2 40mg/m Date HPRA Approval: September 2017 Page 7 of 7
Guidance for Pharmacists on Safe Supply of Oral Methotrexate
Guidance for Pharmacists on Safe Supply of Oral Methotrexate Pharmaceutical Society of Ireland Version 2 January 2015 Contents 1. Introduction 2 2. Methotrexate 2 3. Guidance 2 3.1 Patient Review 2 3.2
More informationMethotrexate. Information for patients. Paediatric Rheumatology. Feedback
Feedback We appreciate and encourage feedback. If you need advice or are concerned about any aspect of care or treatment please speak to a member of staff or contact the Patient Advice and Liaison Service
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate)
PACKAGE LEAFLET: INFORMATION FOR THE USER Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate) Read all of this leaflet carefully before you start using this medicine
More informationPackage leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)
Package leaflet: Information for the user Colecalciferol 3000 IU/ml Oral Solution (colecalciferol) Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationLEUCOVORIN-TEVA 10 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION folinic acid as the calcium salt PACKAGE LEAFLET: INFORMATION FOR THE USER
LEUCOVORIN-TEVA 10 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION folinic acid as the calcium salt PACKAGE LEAFLET: INFORMATION FOR THE USER Read all of this leaflet carefully before you start using this
More informationPackage Leaflet: Information for the User Mercaptopurine 50mg tablets 6-mercaptopurine
Package Leaflet: Information for the User Mercaptopurine 50mg tablets 6-mercaptopurine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase
Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion idursulfase This medicine is subject to additional monitoring. This will allow quick identification of new
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains
More informationPackage leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium
Package leaflet: Information for the patient Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion Active substance: Heparin Sodium Read all of this leaflet carefully before you are given
More informationPackage leaflet: Information for the user. Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion topotecan
Package leaflet: Information for the user Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion topotecan Read all of this leaflet carefully before you start using this medicine because it
More informationALLMERCAP. Consumer Medicine Information (CMI) What is in this leaflet. What ALLMERCAP is used for. Before you take it
mercaptopurine 20 mg/ml oral suspension Consumer Medicine Information (CMI) ALLMERCAP What is in this leaflet This leaflet answers some common questions about ALLMERCAP. It does not contain all of the
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Taltz 80 mg solution for injection in pre-filled syringe ixekizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationPackage leaflet: Information for the user. Jylamvo 2 mg/ml oral solution methotrexate
Package leaflet: Information for the user Jylamvo 2 mg/ml oral solution methotrexate Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationPackage leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains
More informationUser Package Leaflet for Treosulfan 5 g Powder for Solution for Injection or Infusion
User Package Leaflet for Treosulfan 5 g Powder for Solution for Injection or Infusion Please read this leaflet carefully, it is a summary of the information about treosulfan that could be important to
More informationPOLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011
POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen Sugar Free 125mg/5ml and 250mg/5ml Powder for Oral Solution Phenoxymethylpenicillin Read all of this leaflet carefully before you start taking this medicine
More informationEloxatin Oxaliplatin concentrated solution for injection
Eloxatin Oxaliplatin concentrated solution for injection Consumer Medicine Information Please read this leaflet before you are given this medicine. What is in this leaflet This leaflet answers some common
More informationPackage leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate
Package leaflet: Information for the user Exembol 1 mg/ml solution for infusion argatroban monohydrate Read all of this leaflet carefully before you start using this medicine because it contains important
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Menveo powder and solution for solution for injection Meningococcal Group A, C, W135 and Y conjugate vaccine Read all of this leaflet carefully before you or your
More informationAll medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have.
Triprim Tablets Trimethoprim Tablets Consumer Medicine Information What is in this leaflet? The leaflet answers some common questions about Triprim tablets. It does not contain all the available information
More informationPackage leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine
Package leaflet: Information for the patient Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine Read all of this leaflet carefully before you start taking
More informationPemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)
Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet
More information2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient
Package Leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start taking this medicine
More informationPackage leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab
Package leaflet: Information for the user Portrazza 800 mg concentrate for solution for infusion necitumumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol
PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need
More informationPATIENT INFORMATION BOOKLET
PATIENT INFORMATION BOOKLET GETTING STARTED WITH YOUR MEDICINES TIVICAY (dolutegravir) + lamivudine Tivicay is subject to additional monitoring. This will allow quick identification of new safety information.
More informationAll medicines have risks and benefits. Your doctor has weighed the possible risks of using SALOFALK against the expected benefits.
SALOFALK enema mesalazine Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SALOFALK. It does not contain all of the available information. Reading
More informationPackage leaflet: Information for the user. Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride
Package leaflet: Information for the user Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride Read all of this leaflet carefully before you start using this medicine because it
More informationPackage leaflet: Information for the user. multibic potassium-free solution for haemodialysis/haemofiltration
Package leaflet: Information for the user multibic potassium-free solution for haemodialysis/haemofiltration Read all of this leaflet carefully before you start using this medicine because it contains
More informationPackage leaflet: Information for the user. Methylthioninium chloride Proveblue 5 mg/ml solution for injection Methylthioninium chloride
Package leaflet: Information for the user Methylthioninium chloride Proveblue 5 mg/ml solution for injection Methylthioninium chloride Read all of this leaflet carefully before you are given this medicine
More informationIBS Relief 135 mg Tablets Mebeverine Hydrochloride
PATIENT INFORMATION LEAFLET IBS Relief 135 mg Tablets Mebeverine Hydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription.
More informationPackage leaflet: Information for the user Phosex 1000 mg Tablets Calcium acetate
PACKAGE LEAFLET 1 Package leaflet: Information for the user Phosex 1000 mg Tablets Calcium acetate Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationWhat is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?
1 of 5 6/10/2016 3:46 PM Generic Name: bortezomib (bor TEZ oh mib) Brand Name: Velcade What is bortezomib? Bortezomib interferes with the growth of some cancer cells and keeps them from spreading in your
More informationHavrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe
GSK (logo) Package Leaflet: Information for the User Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed). 1440 ELISA Units/1 ml Suspension for Injection in a pre-filled syringe Read all
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER Human Albumin Biotest 20%, solution for infusion Human albumin Read this entire leaflet carefully before you start using this medicine, because it contains important
More informationPackage leaflet: Information for the patient. ERWINASE 10,000 Units, Powder for solution for injection
PACKAGE LEAFLET 1 Package leaflet: Information for the patient ERWINASE 10,000 Units, Powder for solution for injection (Asparaginase from Erwinia chrysanthemi; Erwinia L-asparaginase) Read all of this
More informationPackage leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )
Package leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start
More informationPackage leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains important
More informationPackage leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate
Package leaflet: Information for the user 100 mg/ml concentrate for solution for infusion argatroban monohydrate Read all of this leaflet carefully before you start using this medicine because it contains
More informationArtesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection
More informationActemra concentrate for intravenous infusion
Consumer Medicine Information Actemra concentrate for intravenous infusion Tocilizumab 80 mg in 4 ml, 200 mg in 10 ml and 400 mg in 20 ml concentrate for solution for infusion What is in this leaflet This
More informationPackage leaflet: Information for the user. Calcium Folinate 10 mg/ml, solution for injection Calcium folinate
Package leaflet: Information for the user Calcium Folinate 10 mg/ml, solution for injection Calcium folinate Read all of this leaflet carefully before you start using this medicine because it contains
More informationPackage leaflet: Information for the user. GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon
Package leaflet: Information for the user GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon Read all of this leaflet carefully before you are given this injection because it
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection
PACKAGE LEAFLET: INFORMATION FOR THE USER Calcium Folinate 10 mg/ml Injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again.
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lartruvo 10 mg/ml concentrate for solution for infusion olaratumab This medicine is subject to additional monitoring. This will allow quick identification of new
More information1. What Octostim Nasal Spray is and what it is used for
Package Leaflet: Information for the User Octostim 1.5 mg/ml Nasal Spray Desmopressin acetate Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Paracodin 0.20% w/w Syrup (dihydrocodeine hydrogen tartrate)
PACKAGE LEAFLET: INFORMATION FOR THE USER Paracodin 0.20% w/w Syrup (dihydrocodeine hydrogen tartrate) Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPackage leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin
Package leaflet: Information for the patient NEGABAN 1g, powder for solution for injection or infusion Temocillin Read all of this leaflet carefully before you start using this medicine because it contains
More informationLISINOPRIL-GA tablets 2.5 mg, 5 mg, 10 mg, 20 mg. Lisinopril dihydrate
LISINOPRIL-GA tablets 2.5 mg, 5 mg, 10 mg, 20 mg. Lisinopril dihydrate WHAT IS IN THIS LEAFLET This leaflet answers some common questions about LISINOPRIL-GA. It does not contain all the available information.
More information1. What Betahistine dihydrochloride tablets is and what it is used for
Package leaflet: Information for the user Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets Betahistine dihydrochloride Read all of this leaflet carefully before you start
More informationPackage leaflet: Information for the user. Floxapen 250 mg & 500 mg Capsules. Flucloxacillin
Package leaflet: Information for the user Floxapen 250 mg & 500 mg Capsules Flucloxacillin Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY
CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that
More informationPackage leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine
Package leaflet: Information for the patient Histaclar 10 mg Film-coated Tablets loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. /.../ 50 mg powder and solvent for solution for injection/infusion. melphalan
Package leaflet: Information for the user /.../ 50 mg powder and solvent for solution for injection/infusion melphalan Read all of this leaflet carefully before you start using this medicine because it
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION. ixekizumab
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION Pr TALTZ ixekizumab www.lilly.ca Lilly Read this carefully before you start taking TALTZ and each time you
More informationArtesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun 60mg * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name tamoxifen citrate (tuh-mok-sih-fen SIH-trayt) Brand name Soltamox (SOL-ta-mox) Approved uses Tamoxifen is used to treat certain types of hormone-dependent breast cancer
More informationMedicinal product no longer authorised
EMA/764409/2015 Summary of the risk management plan (RMP) for Ionsys (fentanyl) This is a summary of the risk management plan (RMP) for Ionsys, which details the measures to be taken in order to ensure
More informationSodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride
Package leaflet: Information for the user Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride Read all of this leaflet carefully before using this medicine because it
More informationLGP CLASSIC Oil Products
LGP CLASSIC Oil Products Patient Information Leaflet (PIL) PRODUCT RANGE Medicinal Cannabis Oil Extract LGP CLASSIC 10:10 LGP CLASSIC 10:15 LGP CLASSIC 20:5 What is in this leaflet Please read this leaflet
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Accord 20 mg/ml Concentrate for Solution for Infusion Etoposide
PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Accord 20 mg/ml Concentrate for Solution for Infusion Etoposide Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPatient Guide. This PATIENT GUIDE comes with your Binosto 70mg Effervescent Tablets pack. Please read it carefully.
Patient Guide This PATIENT GUIDE comes with your Binosto 70mg Effervescent Tablets pack. Please read it carefully. BIN-15-002 Patient Leaflet DL (Logo).indd 1 17/12/2015 15:29 Binosto 70mg Effervescent
More informationPackage leaflet: Information for the patient. Xofigo 1100 kbq/ml solution for injection radium Ra 223 dichloride
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end
More informationPackage leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil
Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil Read all of this leaflet carefully before you start using this medicine because
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name letrozole (LEH-truh-zole) Brand name Femara (FEH-muh-ruh) Approved uses Letrozole is used in the treatment of certain types of hormone-dependent breast cancer in postmenopausal
More informationOtezla (apremilast) film coated tablets
New Zealand Consumer Medicine Information Otezla (apremilast) film coated tablets WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Otezla. It does not contain all the available
More informationIn the Republic of Ireland, side effects can be reported online at or directly to the HPRA by calling (01)
MAVENCLAD 10 mg Tablets (cladribine) Patient Guide IMPORTANT INFORMATION ON MINIMISING THE RISK OF ADVERSE EVENTS Reporting of side effects If you get any side effects, talk to your doctor, pharmacist
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed
More informationRELISTOR. Methylnaltrexone bromide, Subcutaneous solution for injection. Consumer Medicine Information
RELISTOR Methylnaltrexone bromide, Subcutaneous solution for injection Consumer Medicine Information What is in this leaflet? This leaflet answers some common questions about RELISTOR. It does not contain
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) METHOTREXATE ORION 2.5 MG & 10 MG TABLET (METHOTREXATE DISODIUM) DATE: , VERSION 1.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) METHOTREXATE ORION 2.5 MG & 10 MG TABLET (METHOTREXATE DISODIUM) DATE: 23-6-2016, VERSION 1.2 VI.2 Elements for a Public Summary Methotrexate is indicated for:
More informationPackage leaflet: Information for the user. Qutenza 179 mg cutaneous patch capsaicin
Package leaflet: Information for the user Qutenza 179 mg cutaneous patch capsaicin Read all of this leaflet carefully before you start using this medicine because it contains important information for
More informationPackage leaflet: Information for the user. ReoPro 2 mg/ml solution for injection or infusion. abciximab
Package leaflet: Information for the user ReoPro 2 mg/ml solution for injection or infusion abciximab Read all of this leaflet carefully before you start using this medicine because it contains important
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationPackage Leaflet: Information for the User. Read all of this leaflet carefully because it contains important information for you.
ASPIRIN 300mg Effervescent Tablets Acetylsalicylic acid (Aspirin) Package Leaflet: Information for the User Read all of this leaflet carefully because it contains important information for you. This medicine
More informationImodium 1 mg/5 ml oral solution
PACKAGE LEAFLET: INFORMATION FOR THE USER Imodium 1 mg/5 ml oral solution Loperamide hydrochloride Imodium is a registered trademark Read all of this leaflet carefully before you start using this medicine
More informationPackage leaflet: Information for the patient. Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib
Package leaflet: Information for the patient Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib This medicine is subject to additional monitoring. This will allow quick identification
More information1. What Faslodex is and what it is used for
Package leaflet: Information for the user Faslodex 250 mg solution for injection Fulvestrant Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationRANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets RANITIDINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationPackage leaflet: Information for the user. Cyanokit 5 g powder for solution for infusion hydroxocobalamin
Package leaflet: Information for the user Cyanokit 5 g powder for solution for infusion hydroxocobalamin Read all of this leaflet carefully before using this medicine because it contains important information
More informationGenRx Amoxycillin Suspension
GenRx Amoxycillin Suspension Contains the active ingredient, amoxycillin (a-mox-i-sil'lin) For a copy of a large print leaflet, Ph: 1800 195 055 Consumer Medicine Information What is in this leaflet Read
More informationZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection
PACKAGE LEAFLET: INFORMATION FOR THE USER ZANOSAR 1g STREPTOZOCINE Lyophilised powder for solution for injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationPackage leaflet: Information for the user. Carmellose sodium
Package leaflet: Information for the user CELLUVISC 0.5% w/v, eye drops, solution, unit dose Carmellose sodium Read all of this leaflet carefully before you start using this medicine because it contains
More informationCLINICAL AUDIT. The safe and effective use of. Methotrexate
CLINICAL AUDIT The safe and effective use of Methotrexate Valid to October 2019 bpac nz better medicin e Background Methotrexate is an immunosuppressant used in the treatment of rheumatoid arthritis, severe
More informationOral Systemic Therapy
Oral Systemic Therapy This information does not take the place of the care and advice of your Cancer Care Team. Talk to your Cancer Care Team about your health concerns, treatment options and any questions
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationIMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS ON SAFETY AND RISK MINIMISATION FOR INFLIXIMAB
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen dulaglutide This medicine is subject to
More informationPackage leaflet: information for the user. Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration
Package leaflet: information for the user Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration Calcium chloride dihydrate/ magnesium chloride hexahydrate/ glucose monohydrate/ lactic
More informationOral Systemic Therapy
Patient & Family Guide 2018 Oral Systemic Therapy www.nscancercare.ca Patient s Name: Type of Treatment: Cancer Doctor: Cancer Clinic: Phone Number: Emergency Department Phone Number: Who do I call if
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Rhesonativ 750 IU/ml, solution for injection Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the user. Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion. piperacillin / tazobactam
Package leaflet: Information for the user Piperacillin/Tazobactam Actavis 2 g / 0.25 g powder for solution for infusion Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion piperacillin
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral)
PACKAGE LEAFLET: INFORMATION FOR THE USER DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral) Read all of this leaflet carefully before you start using
More informationPatient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR
Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any
More informationPACKAGE LEAFLET. Page 1 of 8
PACKAGE LEAFLET Page 1 of 8 Package leaflet: Information for the patient Temazepam 10mg and 20mg tablets (Temazepam) Read all of this leaflet carefully before you start taking this medicine because it
More information